治療頭暈 Cognitive disorders.
Cortical myoclonus, adjunctive.
Vertigo(UTD)

Antimyoclonic, Miscellaneous; Nootropic.

Distribution :
VD: 0.6 L/kg
Metabolism:
Piracetam is not metabolized in the body
Elimination Half-life:
5 to 6 hours.

Previous hypersensitivity to piracetam
Huntington's chorea.

Fetal risk cannot be ruled out.(MDX)

Infant risk cannot be ruled out.(MDX)

NAUSEA, GASTRIC DISCOMFORT, ABDOMINAL PAIN, and FLATULENCE have been described occasionally during piracetam therapy.
High doses of piracetam have been associated with HYPERSTIMULATION, SLEEP DISTURBANCES, and DIZZINESS in some patients .

Cognitive disorders: 1.2 to 4.8 g daily in 2 to 4 divided doses.
Cortical myoclonus, adjunctive: Initial: 7.2 g daily administered in 2 to 3 divided doses; may increase total daily dose by 4.8 g every 3 to 4 days if needed (maximum daily dose: 24 g).
Vertigo: 2.4 to 4.8 g daily in 2 to 3 divided doses.(UTD)

pharmacokinetic studies in these patients are lacking.